From GlobeNewswire: 2024-11-11 16:05:00

Crinetics Pharmaceuticals granted 99,500 stock options to new non-executive employees under the 2021 Inducement Plan, with an exercise price of $60.69 per share. The shares will vest over four years, subject to continued employment. Crinetics focuses on developing therapeutics for endocrine diseases, with lead candidate paltusotine in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome, and atumelnant in Phase 2 for congenital adrenal hyperplasia and Cushing’s disease. All drug candidates are orally delivered small molecules resulting from in-house discovery efforts. For investor inquiries, contact Gayathri Diwakar at [email protected], and for media inquiries, contact Natalie Badillo at [email protected].



Read more at GlobeNewswire: Crinetics Pharmaceuticals Announces November 2024